Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Intervacc AB

Market Cap 443M 46.28M 40.36M 37.2M 35M 65.39M 4.37B 65.97M 172M 2.15B 174M 170M 7.53B P/E 2026 *
-5.42x
P/E 2027 * -5.42x
Enterprise Value 356M 37.19M 32.43M 29.9M 28.13M 52.55M 3.51B 53.02M 138M 1.73B 140M 137M 6.05B EV / Sales 2026 *
22.3x
EV / Sales 2027 * 11.6x
Free-Float
80.66%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 70 05/02/2026
Director of Finance/CFO - 06/02/2020
Chief Tech/Sci/R&D Officer - 11/06/2020
Director TitleAgeSince
Director/Board Member 68 01/01/2025
Director/Board Member 72 01/01/2024
Director/Board Member 71 01/01/2023
Change 5-day change 1-year change 3-year change Capi.($)
-2.23%-0.03%+61.34%+109.10% 56.24B
+4.60%+5.85%+54.47%+43.04% 43.76B
-1.44%+5.50%-13.41%-19.24% 23.32B
-2.69%+4.27%-4.47%+379.00% 21.34B
+3.22%+3.77%+19.92%-35.05% 15.75B
-0.67%+1.18%+12.91%-39.22% 15.6B
-1.01%-1.27%+25.52%+171.92% 13.18B
+3.07%+3.59%+25.54% - 12.01B
+4.95%+7.51%+123.21%+249.05% 11.87B
Average +0.87%+3.76%+33.89%+107.33% 23.68B
Weighted average by Cap. +0.50%+3.54%+37.76%+98.07%

Financials

2026 *2027 *
Net sales 16M 1.67M 1.46M 1.34M 1.26M 2.36M 158M 2.38M 6.2M 77.54M 6.27M 6.14M 272M 30M 3.13M 2.73M 2.52M 2.37M 4.43M 296M 4.47M 11.62M 145M 11.76M 11.51M 510M
Net income -81.6M -8.52M -7.43M -6.85M -6.45M -12.04M -805M -12.15M -31.61M -395M -31.99M -31.3M -1.39B -83.3M -8.7M -7.59M -6.99M -6.58M -12.29M -821M -12.4M -32.27M -404M -32.66M -31.96M -1.42B
Net Debt -87M -9.09M -7.93M -7.31M -6.87M -12.84M -858M -12.95M -33.71M -422M -34.11M -33.37M -1.48B -96M -10.03M -8.74M -8.06M -7.58M -14.17M -947M -14.29M -37.19M -465M -37.63M -36.83M -1.63B
Logo Intervacc AB
Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.
Employees
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!